Neulasta

Pfenex Inc (NYSE: PFNX) has a key binary event coming up: mark your calendar for Oct. 7, when the FDA is scheduled to issue its verdict on the company's lead drug candidate. Through its production platform Pfenex Expression Technology, the biotech Pfenex engages in the development of high-value...

October was a volatile month for the markets, and biotech stocks were no exception. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB) had slipped about 17 percent in the period. This compares to S&P 500's 7 percent retreat. As we enter the last leg of the year, here are a few PDUFA...

Mylan NV (NASDAQ: MYL)’s had a rough three years, but one analyst left the pharma company's investor day with fresh optimism. The Rating Leerink analyst Ami Fadia upgraded Mylan from Market Perform to Outperform and maintained a $52 price target. The Thesis By Leerink’s...

Reviewing Amgen, Inc. (NASDAQ: AMGN)'s third-quarter results, Cowen said the results were boring but very safe. The firm maintains its Buy rating and $209 price target for the shares of the company. At the time of writing, shares of Amgen were trading down 1.67 percent at $174.54. Analysts...

Can one man's pain be another man's gain? It seems so. Even within the stock market, this phenomenon is present, seen through sympathy moves, which result in stocks belonging to the same sector/industry or having the same category of products moving either in tandem with each other or in opposite...

Coherus Biosciences Inc (NASDAQ: CHRS) shares were down steeply in pre-market trading after the company announced it has received a complete response letter from the FDA for its abiologic license application, or aBLA, for CHS-1701, a pegfilgrastim biosimilar candidate to Amgen, Inc. (...

The hot biotech space is set to witness a month of brimming activity in June, as several prospective treatment candidates are up on the altar to receive the blessings of the FDA. Two new molecular entities were approved in May, taking the tally for this year to 20. How The Sector Has Fared Thus...

Commenting on Mylan N.V. (NASDAQ: MYL), Barclays said there's understandably reason to be skeptical that the company will win approval for its generic version of Copaxone now after years of promises. That said, the firm thinks Mylan's chances are better than current market expectations. Analysts...

“While new approvals hurt Mylan N.V. (NASDAQ: MYL) on price (during Q3), the company has defended share effectively; a point management highlighted but we believe has been underappreciated,” Barclays’ Douglas D. Tsao said in a note. The analyst maintains an Equal-Weight rating on...

Orphan drugs, drugs intended to prevent, diagnose or treat rare diseases/disorders, are huge sellers for the pharmaceutical industry. NPR, citing data from EvaluatePharma, noted that seven of the 10 best-selling drugs in the United States throughout 2015 were given an orphan drug status. The main...

Bernstein's Aaron Gal initiated Amgen, Inc. (NASDAQ: AMGN) at Market Perform and set a price target of $161. The company will have a hard time offsetting "stiff biosimilar headwinds," Gal noted. Amgen has a very old drug portfolio with G-CSFs, ESAs and Enbrel accounting for over 100 percent of its...